Clinical assessment of kidney function is central to the practice of medicine. Glomerular filtration rate (GFR) is widely accepted as the best index of kidney function in health and disease and accurate values are required for optimal decisionmaking in many clinical settings. GFR is generally not measured in clinical practice, but is estimated from the serum level of an endogenous filtration marker. GFR-estimating equations are useful because they provide a more accurate estimate of measured GFR than the serum level of the filtration marker alone, and they are expressed in the same units as measured GFR, which facilitates clinical decisions based on the level of kidney function.
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Serum creatinine is ordered to estimate the GFR more than 281 million times annually in the USA [1] , and recent reports show that more than 80% of US clinical laboratories now report estimated GFR (eGFR) whenever serum creatinine is ordered [2] . Worldwide estimates are not known, but eGFR is routinely reported in the UK, France and Australia. The majority of laboratories report eGFR using the Modification of Diet in Renal Disease (MDRD) study equation. However, an increasing number of laboratories are now beginning to use the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 creatinine equation [3, 4] (Olivier Allaire, personal communication), which uses the same variables as the MDRD study but is more accurate across the range of GFR [1, 5, 6] . Widespread implementation of GFR estimation would be facilitated by the use of a single equation expressed for the use with standardized creatinine that is accurate over the full range of GFR and applicable throughout the world.
Three years have passed since we first reported the development and validation of the CKD-EPI creatinine equation and proposed that it replace the MDRD study equation for routine eGFR reporting [5] . At that time, there were some who resisted this change, arguing that further validation was needed, that the improvement in accuracy was small, and that there would likely be a newer equation later, so why change now? It is now apparent from an extensive body of literature that the CKD-EPI equation provides a more accurate estimate of measured GFR, it provides a better tool for clinical practice, research and public health, no other widely applicable creatinine-based estimating equation is more accurate, and we are not aware of ongoing efforts to develop an alternative creatinine-based equation for widespread application. In this editorial, we briefly review the physiologic and statistical basis for development and validation of GFR-estimating equations and the literature comparing the MDRD study and CKD-EPI equations for estimating measured GFR, detecting chronic kidney disease (CKD), estimating CKD prevalence and prognosis and guiding therapy. We conclude with considerations for implementing the change from the MDRD study equation to the CKD-EPI equation for reporting eGFR by clinical laboratories. In our opinion, it is clear that the time for change is now.
D E V E LO P M E N T A N D VA L I D AT I O N O F G F R -E S T I M AT I N G E Q U AT I O N S
The goal in developing an estimating equation is to ensure that it performs well not only in the population in which it is developed, but also in populations in which it is intended for use. GFR-estimating equations are derived from regression analysis relating the level of measured GFR to the serum concentration of an endogenous filtration marker and observed clinical and demographic variables that serve as surrogates for the non-GFR determinants of its serum concentration [7] . For example, age, sex, race and body weight are surrogates for creatinine generation from muscle, which affects serum creatinine concentration independently from GFR. The coefficients reflect relationships observed in the development population, and thus the measurement methods and the population used to develop the equation are critical to the performance of the equation in other populations.
Inaccuracy in the estimation of GFR may be due to bias, defined as systematic deviation of estimated GFR compared with measured GFR using the reference ('gold') standard, or due to imprecision, defined as random variation (or 'spread') of estimated GFR values centered around the measured values. Full review of the causes of bias and imprecision is beyond the scope of this article [8] . Critically, bias reflects systematic differences in measurement methods and non-GFR determinants of the filtration marker between the development dataset and the populations in which the equation are to be used. Imprecision reflects inherent limitations in GFR measurement and in using clinical and demographic variables to model non-GFR determinants of the filtration markers.
CO M P A R I S O N O F T H E M D R D S T U DY A N D C K D -E P I C R E AT I N I N E E Q U AT I O N S

Development process and formulation
The MDRD study equation was developed in 1999 using data from a study of 1628 people using non-standardized serum creatinine assays and re-expressed for use with standardized creatinine in 2006 (Table 1) [9] . GFR is estimated from only four variables, serum creatinine, age, sex and race (black versus white and other). Because it was developed in a population with CKD, a linear relationship appeared sufficient to express the relationship of log-GFR to log-serum creatinine across the range of GFR. It now appears that this relationship is more complicated, as multiple studies show that the MDRD study equation systematically underestimates measured GFR in the range of ∼60-120 mL/min/1.73 m 2 and overestimates measured GFR at levels higher than 120 mL/min per 1.73 m 2 . The systematic bias of the MDRD study equation likely reflects higher creatinine generation in the relatively healthy individuals enrolled in the MDRD study compared with individuals with CKD in the general population [10] . For this reason, the MDRD study equation cannot be used for reporting GFR estimates higher than 60-90 mL/min/1.73 m 2 . The CKD-EPI creatinine equation was developed in 2009 using data from 8254 people with and without CKD in 10 studies [5] . The final equation was selected using a rigorous pre-specified process in a separate validation dataset consisting of 3896 people in 16 studies. Although both equations use the same four variables, the forms of these variables result in important differences. In particular, the relationship between log-GFR and log-serum creatinine is expressed as a two-slope spline. The relationship between eGFR and serum creatinine in the CKD-EPI equation is steeper and similar to the MDRD study equation at higher serum creatinine values but less steep at low values, as has been observed in studies of subjects without CKD, such as kidney donors and young people with Type 1 diabetes without albuminuria [11] . Other differences between the CKD-EPI and MDRD study equations include the following: a linear rather than a logarithmic relationship with age, resulting in a steeper slope of eGFR with age and similar GFR estimates at older age; a smaller coefficient for blacks, resulting in lesser differences in GFR estimates between blacks versus white and others; and at low serum creatinine concentrations, a smaller coefficient for women than men, resulting in smaller differences between men and women at higher GFR ranges.
Performance in estimating measured GFR
In the external validation dataset, we showed that the CKD-EPI equation was more accurate than the MDRD study equation, especially at higher ranges of GFR, with a 50% improvement in median bias overall and 70% improvement at GFR >60 mL/min/1.73 m 2 [1, 5] . A recent systematic review of all studies that compared the two equations using standardized creatinine and plasma or urinary clearance of exogenous filtration markers confirmed that the CKD-EPI equation performed better at a higher GFR [6] . At a lower GFR, the MDRD study equation appeared to performed better in most studies, but in our view this difference is not clinically meaningful.
The race coefficient does not capture all of the differences in creatinine generation among racial and ethnic groups, and others have developed modifications to both the CKD-EPI and MDRD study equations to better reduce this bias in some populations [6, 12, 13] . The Japanese modification to the CKD-EPI equation performed better than the Japanese modification of the MDRD study equation [12] . We and others have shown that the CKD-EPI equation performs better than the MDRD study equation in a Chinese population [14, 15] .
Detecting disease
Widespread reporting of eGFR simplifies the recognition of GFR <60 mL/min/1.73 m 2 and detection of CKD. Lesser bias of the CKD-EPI equation compared with the MDRD study equation would lead to fewer false-positive diagnoses of CKD.
The MDRD study equation has been used to estimate CKD prevalence in multiple countries-results generally are in the range of 10-15% [16] . We showed that among 16 032 adult participants in the US National Health and Nutrition Examination Surveys (NHANES 1999 (NHANES -2006 , CKD prevalence was lower using the CKD-EPI equation compared with the MDRD study equations. These findings have been confirmed in several studies, including a recent meta-analysis of data from 1.1 million adults from 25 general population cohorts, 7 highrisk cohorts and 13 CKD cohorts [17, 18] .
Predicting prognosis
Decreased eGFR is now a well-established risk factor for subsequent development of cardiovascular disease (CVD) and mortality, as well as for kidney failure. There has been much debate about whether increased risk is apparent for people with CKD Stage 3a (GFR 45-59 mL/min/1.73 m 
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meta-analysis described above, across the broad array of populations, participants reclassified to higher estimated eGFR categories by the CKD-EPI equation compared with the MDRD study equation had lower incidence rates for all-cause mortality, cardiovascular mortality and end-stage renal disease (ESRD) compared with those not reclassified (Figure 1 ). In particular, using the CKD-EPI equation, patients re-classified from CKD Stage 3a to Stage 2 had a much lower risk of all adverse outcomes compared with those classified as having CKD Stage 3a using both equations. Therefore, the use of the CKD-EPI equation results in more accurate assessment of prognosis as related to the level of eGFR.
Guiding therapy
There have been few studies comparing the effect of these equations on clinical decisions. The Kidney Disease Outcomes Quality Initiative (KDOQI) clinical action plan for CKD is based on stages defined by GFR. Accurate diagnosis of CKD should lead to more appropriate clinical decisions [5, 7] . For example, a recent study by Jain et al. studied referral of patients to nephrologists before and after implementation of reporting estimated GFR computed using the MDRD study equation [20] . The authors noted an increase in referrals, primarily in women. Presumably, fewer false-negative diagnoses of CKD in low-risk patients using the CKD-EPI equation would allow more appropriate nephrology referral.
I M P L E M E N TAT I O N CO N S I D E R AT I O N S
The table compares features of the MDRD study and CKD-EPI equations relevant for widespread implementation. By all criteria, the CKD-EPI equation is preferred. When considering changes for reporting of any analyte, one must consider the impact on both the laboratory and clinician. From the laboratory perspective, the only change required is a one-time adjustment in the computer program to compute estimated GFR. There are no other changes: the test report is the same, the same analyte is assayed and the same variables are used in the computation. While the computer programming may be more complicated than for changing an analyte assay, the required education for revising the estimated GFR computation is less than for changing an assay. For the clinician, the major change is that now GFR estimates will be available for those with estimated GFR >60 mL/min/1.73 m 2 . Here too, there are no other changes, the test report is the same, the same analyte is used and the main limitation remains the effect of non-GFR determinants of serum creatinine.
We implemented the use of the CKD-EPI equation in our hospital in June 2010 in both the inpatient and outpatient setting without any problems. The two largest service providers in the USA have also implemented the CKD-EPI equation, again without any repercussions or concerns by the clinicians [3, 4] . The next step is for national and international organizations to develop tools to assist all clinical laboratories in making this conversion. Some countries, such as France and Australia, are leading the way. In our opinion, it is time for others to follow suit.
CO N C L U S I O N S
We have come a long way since serum creatinine alone was used for GFR estimation. Accumulating evidence lends strong support to the recommendation that the CKD-EPI equation could replace the MDRD study equation for general use and that it should be implemented without further delay [5] . There are few drawbacks to more widespread implementation of the CKD-EPI equation. The impact on information systems is minimal, and the differences observed by clinicians will be equivalent to reporting an analyte using a new assay. The international nephrology community should take a leadership role to guide this change in their respective countries. 
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Despite these improvements in GFR estimation, much uncertainty remains. The main limitation of creatinine-based GFR-estimating equations is imprecision, likely due to non-GFR determinants of serum creatinine and GFR measurement error. Further improvements will likely require the use of multiple filtration markers with non-correlated non-GFR determinants, such as cystatin C in addition to creatinine [15, 21] . In the meantime, we should use the best tools that are available.
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R E F E R E N C E S
O P PO N E N T ' S COMMENTS
We completely agree with Drs Inker and Levey that the MDRD equation's better performance at low measured GFR (mGFR) is clinically insignificant. The same is valid for the CKD-EPI equation at high mGFR since the accuracy within 30% for mGFR > 60 ml/min/1.73 m 2 was similar for both equations [2.3% (2.6%) difference] according to the current published data.
Using results for bias to conclude that an equation is more accurate is misleading when data on accuracy are not presented [1] . Furthermore, comparing bias, precision or accuracy results in various GFR groups created by estimated GFR (eGFR), instead by mGFR, is also misleading because the thus created eGFR groups by each equation represent different populations, and the same is true when comparing the proper chronic kidney disease (CKD) classification performance in CKD stages created by eGFR [1, 2].
We disagree that there is an 'extensive body of literature that the CKD-EPI equation provides more accurate estimate' 'across the range of GFR'. We fully agree that detecting CKD is very important but disagree that a lesser bias will decrease false-positive diagnosing of CKD. Actually, a better accuracy, which combines bias and precision, is needed for proper CKD diagnosis. Further analysis of the current literature in mGFR groups below and above 60 ml/min/1.73 m 2 revealed that the MDRD equation has slightly better accuracy within 30% but the difference is again clinically insignificant (Table 1) . Moreover, at mGFR of 60 ml/min/1.73 m 2 , the accuracy range within 30% is too wide, e.g. eGFR range of 42-78 mL/min/ 1.73 m 2 , to be useful in clinical practice. Obviously, for clinically critical decisions, for example as diagnosing CKD based solely on GFR level for insurability or employability, as determining eligibility of a kidney transplant donor or recipient, or as dosing of medications, when the eGFR value is close to the respective clinically relevant cut-off GFR level, the GFR measurement in a particular patient is essential.
Comparing the performance of eGFR equations to estimate the prevalence of CKD (and its stages) by net reclassification improvement in a population without the confirmatory test, e. g. the mGFR, could be misleading. The observation that one equation estimates lower prevalence rates does not necessarily prove this equation provides more accurate estimate of the CKD prevalence. As recently discussed, the GFR declines with aging and therefore a CKD definition based alone on GFR below 60 mL/min/1.73m 2 is not applicable to all age groups [3] [4] [5] . Applying this specific arbitrary GFR cut-off level [6] in epidemiological studies underestimates in young and overestimates in elderly subjects the CKD prevalence, something that is further amplified by the CKD-EPI equation in comparison to the MDRD one [7] .
In epidemiological and meta-analysis studies [8, 9] , predicting prognosis by correlation or association between the eGFR, as a risk factor, and the cardiovascular disease (CVD) and mortality incidence rates does not imply causation. The fallacy cum hoc ergo propter hoc is unacceptable in the era of evidence-based medicine. It has been well known that CKD and CVD are interchangeable as risk factors, and therefore a causeand-effect relationship is difficult to establish, as it was recently eloquently elaborated [10] . Furthermore, the highest risk for mortality is age, the latter being included in both the CKD-EPI and MDRD equations. Hence, only carefully designed controlled randomized prospective studies with clinically relevant outcomes may answer the question which equation provides better CVD risk assessment.
After carefully reviewing Drs Inker and Levey's arguments, we maintain our conclusion that at present time there is no sufficient data to support the endorsement of using the new CKD-EPI equation instead of the MDRD one.
Meanwhile, the focus should be on which patient has indeed CKD by GFR alone, a healthcare issue with worldwide significant individual, social and financial consequences.
Pierre Delanaye, Hans Pottel, and Rossini Botev R E F E R E N C E S chromium-ethylene diamine tetraacetic acid.
P O L A R V I E W S I N N E P H R O LO GY
E s t i m a t i n g G F R u s i n g t h e C K D -E P I
